EMA Backs EU Approval For Ztalmy & Pylclari Roche Withdraws EU Filing For AMD Implant
Executive Summary
Two new products, one for epilepsy and the other for prostate cancer, were recommended for EU approval during the latest monthly meeting of the European Medicines Agency’s human medicines committee, the CHMP.
You may also be interested in...
EMA Recommends Revoking EU Approval For Novartis’s Sickle Cell Disease Drug
The results of a Phase III study did not confirm the benefits previously seen with Adakveo, the European Medicines Agency said.
EMA: Marinus Filing Up For An Opinion; Amylyx, GSK & Curium Due For Oral Explanations
The European Medicines Agency’s human medicines committee, the CHMP, is meeting this week to discuss the EU marketing applications for a number of products that have reached the late stages of the regulatory review cycle.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.